Stock Scorecard



Stock Summary for Enveric Biosciences Inc (ENVB) - $3.18 as of 5/6/2026 10:36:28 PM EST

Total Score

12 out of 30

Safety Score

30 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ENVB

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ENVB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ENVB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ENVB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ENVB (30 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ENVB

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model 5/5/2026 11:39:00 PM
Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies - Enveric Bioscienc 5/5/2026 12:09:00 PM
Enveric Biosciences Inc - Reports Positive Preclinical Results For Eb-003 In Ptsd Model 5/5/2026 12:09:00 PM
Enveric Biosciences (ENVB) clarifies 1‑for‑15 max reverse split in 2026 proxy 4/30/2026 8:09:00 PM
Enveric Biosciences (Nasdaq:ENVB) - Stock Analysis 4/29/2026 9:39:00 PM
[EFFECT] Enveric Biosciences, Inc. SEC Filing 4/29/2026 9:09:00 PM
Enveric Biosciences (NASDAQ: ENVB) files resale prospectus for 6.82M shares 4/29/2026 9:09:00 PM
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors 4/29/2026 9:09:00 AM
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors 4/28/2026 11:39:00 AM
Fresh off Nasdaq listing, Lakewood-Amedex taps biotech CEO for board 4/28/2026 11:10:00 AM

Financial Details for ENVB

Company Overview

Ticker ENVB
Company Name Enveric Biosciences Inc
Country USA
Description Enveric Biosciences, Inc., a pharmaceutical company, is dedicated to developing various cannabinoid drugs for the treatment of cancer. The company is headquartered in Naples, Florida.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/13/2026

Stock Price History

Last Day Price 3.18
Price 4 Years Ago 374.40
Last Day Price Updated 5/6/2026 10:36:28 PM EST
Last Day Volume 443,281
Average Daily Volume 7,779,766
52-Week High 17.84
52-Week Low 1.71
Last Price to 52 Week Low 85.96%

Valuation Measures

Trailing PE N/A
Industry PE 131.76
Sector PE 81.50
5-Year Average PE -25.60
Free Cash Flow Ratio 1.28
Industry Free Cash Flow Ratio 18.87
Sector Free Cash Flow Ratio 24.59
Current Ratio Most Recent Quarter 5.38
Total Cash Per Share 2.48
Book Value Per Share Most Recent Quarter 3.94
Price to Book Ratio 1.51
Industry Price to Book Ratio 18.90
Sector Price to Book Ratio 9.97
Price to Sales Ratio Twelve Trailing Months 0.08
Industry Price to Sales Ratio Twelve Trailing Months 8.86
Sector Price to Sales Ratio Twelve Trailing Months 4.70
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 1,985,500
Market Capitalization 6,313,890
Institutional Ownership 6.01%

Dividends

Ex-Dividend Date 4/23/2008
Previous Dividend Amount 0.0000
Current Dividend Amount 18,489.4962
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -26.70%
Reported EPS 12 Trailing Months -36.24
Reported EPS Past Year -31.08
Reported EPS Prior Year -4.44
Net Income Twelve Trailing Months -8,771,987
Net Income Past Year -12,131,472
Net Income Prior Year -9,574,987
Quarterly Revenue Growth YOY -7.30%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 4,677,491
Total Cash Past Year 4,677,491
Total Cash Prior Year 2,241,026
Net Cash Position Most Recent Quarter 4,677,491
Net Cash Position Past Year 4,677,491
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 4,177,541
Total Stockholder Equity Prior Year 1,592,807
Total Stockholder Equity Most Recent Quarter 4,177,541

Free Cash Flow

Free Cash Flow Twelve Trailing Months -8,141,546
Free Cash Flow Per Share Twelve Trailing Months -4.10
Free Cash Flow Past Year -8,141,546
Free Cash Flow Prior Year -7,726,139

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.23
RSI 0.00
50-Day SMA 123.44
150-Day SMA 0.00
200-Day SMA 259.88

System

Modified 5/8/2026 10:15:02 PM EST